** Shares of vaccine maker Moderna MRNA.O gain 1.9% to $43.18 premarket
** Co has been awarded tender to supply its mRNA COVID-19 vaccine in the European Union, Norway and North Macedonia, allowing 17 countries to access the vaccine for up to four years
** Tender comes after MRNA cut its 2025 sales forecast by $1 bln earlier this month, partially due to weak demand for its COVID-19 vaccines
** The trim brought co's FY25 revenue forecast below analysts' estimates and sent shares down nearly 17% on Jan. 13
** Seven of 26 brokerages covering stock rate it "buy", 15 rate "hold" and four rate "sell" or lower; median PT is $57 - LSEG data
** MRNA stock more than halved in 2024
(Reporting by Sanchayaita Roy in Bengaluru)
((Sanchayaita.roy@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。